Previous 10 | Next 10 |
Investors can win big when they invest in healthcare stocks that are likely takeover targets. These companies often may not be that profitable, but because of the potential for their products or for their growing revenue, larger companies are willing to pay a premium for them. That often mean...
BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET PR Newswire SAN RAFAEL, Calif. , Feb. 7, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that...
Summary Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA/ RNA nanoparticle deliveries, including treatments for Hemophilia A. Poseida is advancing its broad pipeline with its CAR-T port...
Summary Sangamo's hemophilia A program is not convincing due to durability concerns. Fabry Disease program actually looks more promising. However, Fabry is in an early stage, and we won't see pivotal data for a while. I covered Sangamo ( SGMO ) thrice in the last three...
Summary BioMarin caught a strong bid on the back of its Roctavian label advancing toward FDA approval. Investors reward new product developments, and in biotech/pharma, the prospect of new products, research shows. Hence, there is scope for those speculating on late-stage clinical a...
Summary BioMarin has a core cadre of molecules with modestly growing revenues. Its VOXZOGO has clear blockbuster potential. ROCTAVIAN, which is already approved in the EU, is coming on strong with FDA review pending. BioMarin's outsized market cap and rich P/E ratio are rightly ...
Summary BioMarin Pharmaceutical Inc. revenues for Q3 of 2022 came in at $505.3 million, which was a year-over-year growth of 24%. It has potential to receive U.S. marketing approval of ROCTAVIAN for the treatment of adults with severe Hemophilia A; PDUFA date established for March 31, 2...
Summary Ascendis is a mid-cap commercial biotech based in Denmark. Currently, it trades around $6.7B market cap, and the company holds $900M cash. Skytrofa (TransCon hGh) is Ascendis' lead approved agent for pediatric growth hormone deficiency (GHD), where the commercial update was luke...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The world of pharmaceutical progress happens incrementally and exponentially. That is, therapies are iteratively improved while breakthrough treatments are also created and discovered. Investors who are curious to understand d...
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...